Explanipedia

Finerenone-related risk of hypotension in patients with heart failure with mildly reduced or preserved ejection fraction Open

Alberto Foà, M Vaduganathan, Brian Claggett, Akshay S. Desai, P S Jhund , et al. · 2025

Introduction The non-steroidal MRA finerenone reduces clinical events in heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) but the frequency and implications of treatment-related hypotension are not known. Meth…

Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients Open

Mei‐Zhen Wu, Ran Guo, Chanchal Chandramouli, Lin Liu, Andrew Tung , et al. · 2025

Background and Aims To investigate the impact of incident urinary tract infection (UTI) and subsequent sodium-glucose cotransporter-2 (SGLT2) inhibitors discontinuation on clinical outcomes among patients with type 2 diabetes mellitus (T2D…

Artificial intelligence‐based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis Open

Lucia Venneri, Alberto Aimo, Aldostefano Porcari, İrem Sezer, Adam Ioannou , et al. · 2025

Aims In transthyretin amyloid cardiomyopathy ( ATTR ‐ CM ), reduced stroke volume ( SV ) portends a poor prognosis. Artificial intelligence ( AI ) enables rapid, standardized assessment of left ventricular outflow tract velocity‐time integ…

Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fraction Open

Muthiah Vaduganathan, Brian Claggett, Safia Chatur, Akshay S. Desai, Pardeep S. Jhund , et al. · 2025

Sodium–glucose cotransporter-2 inhibitors (SGLT2i) and the nonsteroidal mineralocorticoid receptor antagonist (nsMRA) finerenone have each been shown to individually improve heart failure events among patients with heart failure and mildly…

Global patterns of polypharmacy after acute heart failure hospitalization: Prevalence and outcomes from the REPORT‐HF registry Open

Wan Ting Tay, Tiew‐Hwa Katherine Teng, Wouter Ouwerkerk, John G.F. Cleland, Sean P. Collins , et al. · 2025

Aims Polypharmacy, defined as the concurrent use of ≥5 medications, is prevalent among older adults with heart failure (HF). While guideline‐directed HF medications provide therapeutic benefits, non‐HF polypharmacy, particularly involving …

Is Type 2 Diabetes a Modifiable Risk Factor for the Evolution and Progression of Heart Failure With a Preserved Ejection Fraction? Open

Milton Packer, Carolyn S.P. Lam, Javed Butler, Faı̈ez Zannad, Muthiah Vaduganathan , et al. · 2025

Characteristics and cardio-renal outcomes in patients with CKD receiving guideline-directed medical therapy: insights from DISCOVER CKD Open

Roberto Pecoits‐Filho, Eiichiro Kanda, Naoki Kashihara, Richard Ofori‐Asenso, Hungta Chen , et al. · 2025

Background and hypothesis In clinical trials, renin–angiotensin system inhibitors (RASi) and sodium-glucose co-transporter-2 inhibitors (SGLT2i), herein referred to as guideline-directed medical therapy (GDMT), alone or in combination, pro…

Effect of Finerenone on Morbidity and Mortality in CKD Open

John W. Ostrominski, Gerasimos Filippatos, B Claggett, Zi Michael Miao, Akshay S. Desai , et al. · 2025

Key Points In three trials, finerenone reduced a range of cardiovascular and kidney outcomes in persons with diabetes and CKD. Benefits of finerenone were observed across a broad spectrum of glycemia and kidney structure and function. In e…

Temporal trends in incidence, clinical characteristics and outcomes among young adults with heart failure: a territory-wide study from 2014 to 2023 on 19,537 patients Open

Wenli Gu, Tiew‐Hwa Katherine Teng, Claire Lawson, Jasper Tromp, Wouter Ouwerkerk , et al. · 2025

Pharmacologic Treatment of Heart Failure With Reduced Ejection Fraction Open

Bart J. van Essen, Daan C H Ceelen, Wouter Ouwerkerk, Tiew‐Hwa Katherine Teng, Ganash N Tharshana , et al. · 2025

Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial Open

Javed Butler, Francesco Fioretti, Ciaran J. McMullan, Kevin J. Anstrom, Irina Barash , et al. · 2025

Background and Aims In the VICTOR trial (NCT05093933), vericiguat was neutral for the primary composite endpoint of cardiovascular death or hospitalization for heart failure (HF). VICTOR was powered to independently assess cardiovascular d…

Effect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF Open

Faı̈ez Zannad, Yogesh N V Reddy, Irina Barash, Kevin J. Anstrom, Marc P. Bonaca , et al. · 2025

Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF Open

Mingming Yang, Alasdair D Henderson, Inder S. Anand, Akshay S. Desai, Carolyn S.P. Lam , et al. · 2025

Aims To investigate the EQ-5D-3L Level Sum Score (LSS) in patients with heart failure (HF) and reduced (HFrEF) and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and the effect of sacubitril/valsartan on this score using pati…

Effects of sacubitril/valsartan on hypertensive heart disease: the REVERSE-LVH randomized phase 2 trial Open

Vivian Lee, Mayank Dalakoti, Qishi Zheng, Desiree‐Faye Toh, Redha Boubertakh , et al. · 2025

Effect of budesonide/glycopyrronium/formoterol fumarate dihydrate on cardiopulmonary outcomes in COPD: rationale and design of the THARROS trial Open

Fernando J. Martinez, John R. Hurst, MeiLan K. Han, David Price, Jinping Zheng , et al. · 2025

Background Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) are leading causes of death with overlapping and syndemic pathophysiological interactions. Inhaled triple therapies containing inhaled corticosteroids…

The effect of sodium‐glucose cotransporter 2 inhibitors on HbA1c variability and cardiovascular and renal adverse outcome in patients with T2DM Open

Ran Guo, Ambarish Pandey, Chanchal Chandramouli, Mei‐Zhen Wu, Anping Cai , et al. · 2025

Aims To compare the effectiveness of sodium‐glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase 4 (DPP‐4) inhibitors in reducing haemoglobin A1c (HbA1c) variability and improving cardiovascular and renal outcomes in patient…

Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction Open

John W. Ostrominski, Jingmei Li, Brian Claggett, Zi Michael Miao, Akshay S. Desai , et al. · 2025

Race and Ethnicity in Heart Failure Trials: Time to Update Recommended Categories for Global Relevance Open

M. Yang, Toru Kondo, Pooja Dewan, Akshay S. Desai, Antonio S. Sibulo , et al. · 2025

Background The collection of race and ethnicity data in clinical trials using standardized categories is recommended by the US Food and Drug Administration, although this is primarily for domestic reasons. The applicability and understandi…

Effect of Efpeglenatide on Heart Failure Outcomes: A Participant-Level Exploratory Analysis of the Randomized AMPLITUDE-O Trial Open

Kelley R. Branch, Carolyn S.P. Lam, Shofiqul Islam, Stefano Del Prato, Renato D. Lópes , et al. · 2025

Authors’ reply to quality of care delivery in patients with acute heart failure Open

Tiew‐Hwa Katherine Teng, Jasper Tromp, Carolyn S.P. Lam · 2025

Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial Open

Misato Chimura, Mingming Yang, Alasdair D Henderson, Pardeep S. Jhund, Kieran F. Docherty , et al. · 2025

Aims Anaemia is common in heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and associated with poor clinical outcomes. While renin–angiotensin system blockers reduce haemoglobin, little is known about the eff…

Heart failure and obesity: Translational approaches and therapeutic perspectives. A scientific statement of the Heart Failure Association of the ESC Open

Gianluigi Savarese, Gabriele G. Schiattarella, Felix Lindberg, Markus S. Anker, Antoni Bayés‐Genís , et al. · 2025

Obesity and heart failure (HF) represent two growing pandemics. In the general population, obesity affects one in eight adults and is linked with an increased risk for HF. Obesity is even more common in patients with HF, where it complicat…

Sex Differences in Diabetic Cardiomyopathy and Treatment Response to AT-001 Open

Vanessa Blumer, James L. Januzzi, Yuxi Liu, Javed Butler, Justin A. Ezekowitz , et al. · 2025

Heart Failure With Preserved Ejection Fraction Phenotype Is Associated With Early Symptom Onset in Aortic Stenosis and Residual Symptoms After Transcatheter Aortic Valve Implantation Open

Constantijn S. Venema, Kees H. van Bergeijk, Jan A. Krikken, Hindrik W. van der Werf, Ad F.M. van den Heuvel , et al. · 2025

Background Aortic stenosis can lead to cardiac adaptations and symptoms similar to heart failure with preserved ejection fraction. We hypothesized that a heart failure with preserved ejection fraction phenotype in aortic stenosis is associ…

Combined circulating microRNA and peptide biomarkers for prognostication in heart failure Open

Lee Lee Wong, Hiromi Wai Ling Koh, Hyungwon Choi, Ruiyang Zou, Lihan Zhou , et al. · 2025

Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial Open

Jawad H. Butt, Pardeep S. Jhund, Alasdair D Henderson, Brian Claggett, Akshay S. Desai , et al. · 2025

Aims Chronic obstructive pulmonary disease (COPD) is associated with worse outcomes in heart failure (HF) with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). A post hoc analysis of TOPCAT suggested that the effectiveness of …

Assessing Benefit in Heart Failure Patients with Reduced Ejection Fraction: Analysis of the VICTORIA Trial Using Novel Prognostic Risk Stratification Open

Christopher M. O’Connor, Sarah Rathwell, Devan V. Mehrotra, Stefano Corda, Ciaran J. McMullan , et al. · 2025

Background Randomized controlled clinical trials remain the gold standard for determining efficacy of new heart failure (HF) therapies; however, failure to account for heterogeneity in risk of the primary endpoint(s) may dilute treatment e…

Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Open

Akshay S. Desai, Pardeep S. Jhund, Muthiah Vaduganathan, Brian Claggett, Jonathan W. Cunningham , et al. · 2025

Importance The mode of death in patients with heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with preserved ejection fraction (HFpEF) remains poorly understood and may vary by EF. Objective To evaluate the mo…

Finerenone and Atrial Fibrillation in Heart Failure Open

Shingo Matsumoto, Alasdair D Henderson, Pardeep S. Jhund, Johann Bauersachs, Ovidiu Chioncel , et al. · 2025

Importance Heart failure (HF) with mildly reduced or preserved ejection fraction and atrial fibrillation (AF) are closely intertwined. Objective To examine the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist f…

FINERENONE, BILIRUBIN, AND HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION: AN ANALYSIS FROM FINEARTS-HF Open

Jawad H. Butt, Alasdair Henderson, Brian Claggett, Akshay S. Desai, Carolyn S.P. Lam , et al. · 2025

Carolyn S.P. Lam YOU? Author Swipe